A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

BACKGROUND: Mechanistic target of rapamycin (mTOR) pathway is essential for the growth of gastric cancer (GC), but mTOR inhibitor everolimus was not effective for the treatment of GCs. The Cancer Genome Atlas (TCGA) researchers reported that most diffuse-type GCs were genomically stable (GS). Pathol...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Exp Clin Cancer Res
Hoofdauteurs: Fukamachi, Hiroshi, Kim, Seon-Kyu, Koh, Jiwon, Lee, Hye Seung, Sasaki, Yasushi, Yamashita, Kentaro, Nishikawaji, Taketo, Shimada, Shu, Akiyama, Yoshimitsu, Byeon, Sun-ju, Bae, Dong-Hyuck, Okuno, Keisuke, Nakagawa, Masatoshi, Tanioka, Toshiro, Inokuchi, Mikito, Kawachi, Hiroshi, Tsuchiya, Kiichiro, Kojima, Kazuyuki, Tokino, Takashi, Eishi, Yoshinobu, Kim, Yong Sung, Kim, Woo Ho, Yuasa, Yasuhito, Tanaka, Shinji
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2019
Onderwerpen:
Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6416873/
https://ncbi.nlm.nih.gov/pubmed/30866995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1121-3
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items